How to turn a possibility into reality
Innovation, entrepreneurship and IP commercialisation are fundamental elements of the Curtin research mindset. We have a growing cohort of researchers who are engaged and interested in commercialisation opportunities. We’re supporting these researchers and their collaborators through a range of mechanisms that enable and foster their ideas from conception to commercial success.
The commercialisation process
All commercial prospects disclosed to us by Curtin researchers are managed through a diligent, methodical process and assessed by an expert advisory board.
Commercial opportunities
We’re looking for investment, collaboration and licensing partners for several technologies.
Support for entrepreneurs and start-ups
The three Curtinnovation programs – Ignition, Accelerate and Kickstart – are designed to help aspiring entrepreneurs at different stages of the commercialisation process.
Curtinnovation Awards
The Curtinnovation Awards identify new technologies, products and services arising from research at Curtin or its collaborators.
Key people
Rohan McDougall
Paul Nicholls
Our success stories
Over the past decade, we’ve helped nurture 24 research projects into successful commercial ventures. Here’s just a few:
Neuromonics helps provide people with tinnitus to improve their quality of life and overcome challenges associated with the condition.
Sensear markets a range of products that enable effective communication in high noise environments.
HiSeis specialises in cost effective, high-definition seismic reflection techniques for end-to-end seismic hard rock exploration.
HyprFire is software that works to prevent cyber-attacks by using powerful statistical techniques to identify and filter out malicious traffic while keeping the online service running.
iCetana supplies AI assisted video monitoring software to improve security and autonomous operations.
Renergi Pty Ltd commercialises biomass and waste to energy technologies.
PainChek has developed the world’s first smart phone pain assessment and monitoring device. The company listed on the ASX in 2016.
Selvax is developing a novel immunological based approach to the treatment of cancer. The treatment is being investigated for animal health and human medical issues.
REXOrtho is developing the REX Screw product range for use in orthopaedic surgical applications.